{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81.9"},{"groupId":"OG001","value":"72.8"},{"groupId":"OG002","value":"85.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1923"},{"groupId":"OG001","value":"662"},{"groupId":"OG002","value":"466"}],"units":"Participants"}],"description":"An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine was also an AE. AEs such as redness, swelling, and pain/tenderness/soreness at the injection site were recorded.","groups":[{"description":"9-valent human papillomavirus (9vHPV) L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lots 1, 2, or 3.","id":"OG000","title":"9- to 15-Year-Old Females (Lots 1, 2 or 3)"},{"description":"9vHPV L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered was obtained from manufacturing Lot 1.","id":"OG001","title":"Base Study: 9- to 15-Year-Old Males (Lot 1)"},{"description":"9vHPV L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered was obtained from manufacturing Lot 1.","id":"OG002","title":"Base Study: 16- to 26-Year-Old Females (Lot 1)"}],"paramType":"NUMBER","populationDescription":"All participants who received at least one dose of 9vHPV vaccine and had available follow-up data. Per protocol, this outcome measure included data from 9- to 15-year-old females regardless of lot administered.","reportingStatus":"POSTED","timeFrame":"Up to 5 days after any vaccination","title":"Base Study: Percentage of Participants With Injection Site Adverse Experiences (AEs)","type":"PRIMARY","unitOfMeasure":"Percentage of Participants"}